Oragenics (OGEN) Current Deferred Revenue (2010 - 2016)
Oragenics' (OGEN) quarterly Current Deferred Revenue came in at $17687.0 in Q1 2016, up 2.38% YoY from $17276.0 in Q2 2015, and up 24.42% on a QoQ basis from $14215.0 in Q4 2015.
Oragenics (OGEN) Current Deferred Revenue (2010 - 2016) Analysis & Trends
Oragenics (OGEN) has 7 years of Current Deferred Revenue data on file, last reported at $17687.0 in Q1 2016.
- Quarterly Current Deferred Revenue rose 2.38% year-over-year to $17687.0 in Q1 2016, while the trailing twelve-month figure through Mar 2016 was $17687.0 (up 2.38% YoY) and the FY2015 annual result came in at $14215.0, down 33.02% from the prior year.
- Current Deferred Revenue grew to $17687.0 in Q1 2016, from $14215.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $145196.0 in Q1 2012 to a low of $14215.0 in Q4 2015.
- A 5-year average of $34310.3 and a median of $22184.5 in 2013 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2012 — Current Deferred Revenue tumbled 66.67% — and 2014, when it jumped 67.95%.
- Tracing OGEN's Current Deferred Revenue over 5 years: stood at $50989.0 in 2012, then sank by 63.05% to $18839.0 in 2013, then climbed by 12.65% to $21222.0 in 2014, then slumped by 33.02% to $14215.0 in 2015, then grew by 24.42% to $17687.0 in 2016.
- The last three Current Deferred Revenue figures came in at $17687.0 (Q1 2016), $14215.0 (Q4 2015), and $15339.0 (Q3 2015), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Oragenics | 2.38 Mn | 2.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | 17,687.00 |
| Dec 31, 2015 | 14,215.00 |
| Sep 30, 2015 | 15,339.00 |
| Jun 30, 2015 | 17,855.00 |
| Mar 31, 2015 | 17,276.00 |
| Dec 31, 2014 | 21,222.00 |
| Sep 30, 2014 | 25,592.00 |
| Jun 30, 2014 | 38,876.00 |
| Mar 31, 2014 | 50,400.00 |
| Dec 31, 2013 | 18,839.00 |
| Sep 30, 2013 | 23,711.00 |
| Jun 30, 2013 | 23,147.00 |
| Dec 31, 2012 | 50,989.00 |
| Mar 31, 2012 | 145,196.00 |
| Dec 31, 2011 | 152,962.00 |
| Sep 30, 2011 | 161,385.00 |
| Jun 30, 2011 | 115,594.00 |
| Dec 31, 2010 | 13,188.00 |